Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy: A Randomized Controlled Trial

What this Trial Is About

This research aims to compare the effects of two medications, intravenous labetalol and lignocaine, on heart rate and blood pressure changes during laryngoscopy and intubation in patients undergoing elective laparoscopic cholecystectomy. The study focuses on adults with good physical status (ASA Grade I and II) aged 18 to 60, investigating which drug better maintains cardiovascular stability during this procedure by limiting heart rate and mean arterial pressure changes to within ±20% of baseline values. Participants will be randomly assigned to receive either labetalol at a dose of 0.25 mg/kg or lignocaine at 1.5 mg/kg. Both drugs are administered intravenously over 60 seconds, three minutes before laryngoscopy and intubation. The study will track blood pressure and heart rate from five minutes before induction until ten minutes after intubation, recording any adverse events such as bradycardia, hypotension, or allergic reactions. During the study, researchers will monitor systolic and diastolic blood pressures, mean arterial pressure, and heart rate closely around the time of airway instrumentation. They will also observe the use of any rescue medications and note adverse events from induction through recovery, approximately one hour. The findings aim to guide anesthesiologists in selecting the safer and more effective medication to control hemodynamic responses during laparoscopic surgery.

Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy